Under construction – not a live service

Skip to content

Frontlight Research

Institution

Hôpital Saint-Louis

Paris, FranceWebsite

Also known as: CHU Saint-Louis · CHU St-Louis · Hôpital St-Louis

264running trials
140closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

No trial has been confirmed here yet.

Running trials

Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Source
Recruiting
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
NCT07672769· Phase 2· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· Source
Not yet recruiting
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NCT07463768· Phase 2· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Source
Not yet recruiting
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07359456· Phase 2· Source
Recruiting
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173· Phase 1· Source
Recruiting
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· Phase 3· Source
Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680· Phase 2· Source
Not yet recruiting
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
NCT07284394· Phase 3· Source
Recruiting
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
NCT07771855· Phase 2· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Source
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
2025-524014-29-00· Phase 3· Source
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· Phase 2/3· Source
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694· Phase 1· Source
Recruiting
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
NCT07292012· Phase 4· Source
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772· Phase 1/2· Source
Recruiting
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)
NCT05986071· Phase 1/2· Source
Not yet recruiting
Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
NCT07337447· Phase 2· Source
Recruiting
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
NCT07124858· Source
Recruiting
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· Phase 2· Source
Recruiting
Early detection of triple negative breast cancer relapse (CUPCAKE)
2022-501562-22-01· Phase 2· Source
Recruiting
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
NCT06225505· Source
Not yet recruiting
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
NCT07347210· Phase 2· Source
Not yet recruiting
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
NCT07379957· Source
Not yet recruiting
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· Phase 2· Source
Recruiting
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
NCT07157670· Source
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831· Phase 2/3· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Source
Recruiting
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
NCT07044453· Phase 2/3· Source
Recruiting
Dapagliflozin for Cardio-renal Protection After ICU Discharge
NCT07025629· Phase 3· Source
Not yet recruiting
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
NCT06281847· Phase 1/2· Source
Recruiting
Momelotinib in VEXAS Syndrome
NCT07098936· Phase 2· Source
Recruiting
Momelotinib in VEXAS syndrome
2024-519779-24-00· Phase 2· Source
Recruiting
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027· Phase 2· Source
Recruiting
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· Phase 2· Source
Not yet recruiting
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
2025-521322-14-00· Phase 2· Source
Recruiting
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT06599411· Source
Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465· Phase 2· Source
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· Phase 3· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· Source
Not yet recruiting
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
NCT07082452· Phase 3· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Source
Recruiting
Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus
NCT06876467· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· Source

Showing 50 of 264.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Source
Not yet recruiting
Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma
NCT06933966· Phase 2· Source
Completed
Infectious Complications After Esophagectomy
NCT06911658· Source
Completed
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05896163· Phase 1/2· Source
Completed
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma
2024-511949-19-00· Phase 1· Source
Completed
IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment
NCT05066607· Phase 2· Source
Completed
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
NCT06447506· Phase 2· Source
Completed
FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
NCT06592846· Source
Active, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· Phase 2· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Source
Completed
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis
NCT05999799· Phase 2· Source
Completed
A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839· Phase 1· Source
Completed
A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer
NCT04916002· Phase 2· Source
Completed
SafeHeal Diverting Ileostomy Pivotal Study
NCT06152276· Source
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318· Source
Completed
AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS
NCT04553692· Phase 1· Source
Terminated
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
NCT05625087· Phase 2· Source
Completed
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.
2022-502372-22-01· Phase 2· Source
Completed
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
NCT05487248· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· Phase 2· Source
Completed
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression
NCT03779230· Phase 1/2· Source
Completed
Ophthalmological Adverse Events of Tralokinumab in AD
NCT05682976· Source
Completed
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT05583552· Phase 2· Source
Completed
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
NCT05383170· Phase 1/2· Source
Completed
Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial
2022-501179-23-00· Phase 4· Source
Completed
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
NCT05642208· Phase 4· Source
Completed
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
NCT05577182· Phase 1· Source
Completed
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT05656911· Phase 2· Source
Completed
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy
2022-500652-37-00· Phase 2· Source
Completed
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882· Phase 3· Source
Terminated
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NCT05568225· Phase 2· Source
Active, not recruiting
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446· Phase 2· Source
Withdrawn
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
NCT05572463· Phase 1/2· Source
Completed
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)
NCT05111626· Phase 3· Source
Active, not recruiting
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134· Phase 2· Source
Completed
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
NCT05393037· Phase 3· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Source
Completed
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
2023-508357-58-00· Phase 1/2· Source
Completed
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
NCT05172596· Phase 2· Source
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· Phase 2· Source
Completed
Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1)
NCT04905407· Phase 2· Source
Completed
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
NCT05116202· Phase 1/2· Source
Completed
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
NCT04988841· Phase 2· Source
Terminated
SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study
NCT05010850· Source
Terminated
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
NCT04586244· Phase 2· Source
Completed
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
NCT04984356· Phase 1· Source
Completed
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
NCT05070208· Source
Completed
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
2023-503624-83-00· Phase 1/2· Source
Terminated
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
NCT04949256· Phase 3· Source
Completed
A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
NCT04822350· Source

Showing 50 of 140.

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 049am9t04 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Hôpital Saint-Louis: trials and research groups – Frontlight Research